Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 101Neoplasms, Plasma Cell 12Recurrence 9Lymphoma 8Immunoglobulin Light-chain Amyloidosis 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myeloid, Acute 5Lymphoma, Mantle-Cell 4Waldenstrom Macroglobulinemia 3Paraproteinemias 3Hematologic Neoplasms 3Amyloidosis 3Renal Insufficiency 2Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Burkitt Lymphoma 2beta-Thalassemia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Thalassemia 1Sarcoma, Myeloid 1Prostatic Neoplasms 1Plasmacytoma 1Plasmablastic Lymphoma 1Peripheral Nervous System Diseases 1

Interventions

Cytarabine 4venetoclax 2Mitoxantrone 2Daunorubicin 2Cladribine 2thymoglobulin 1quizartinib 1pegylated granulocyte colony-stimulating factor 1fludarabine phosphate 1fludarabine 1blinatumomab 1Transplantation 1Thiotepa 1Tacrolimus 1Sorafenib 1Sirolimus 1Rituximab 1Razoxane 1Mesna 1Melphalan 1Leyk 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1Etoposide 1Dexrazoxane 1Cyclophosphamide 1Bortezomib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × Bortezomib × 1 year × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡